An ongoing dialogue on HIV/AIDS, infectious diseases,
January 13th, 2009
Can We Have “Too Many Options?”
As part of our regular series “Antiretroviral Rounds” in AIDS Clinical Care, today we post a case of a highly treatment-experienced patient with dreaded “triple class” resistance — that is, resistance to NRTIs, NNRTIs, and PIs.
The good news now, of course, is that we have more than these three drug classes.
The tough part is choosing what to use, as often with so many new options we’re designing regimens that have not been extensively tested in prospective studies. (Or tested at all — for example, no patient in the maraviroc MOTIVATE studies received darunavir; today I’d suspect nearly every patient on this drug is on darunavir.)
We asked three highly-experienced HIV specialists what they’d do for a patient like this with “too many options” — raltegravir-naive, R5 tropic virus, susceptibility to both etravirine and darunavir — and perhaps not surprisingly, we got three different answers.
Further input to management of this case is welcome, of course.
Categories: Antiretroviral Rounds, HIV, Patient Care
Tags: darunavir, etravirine, HIV, maraviroc, raltegravir, resistance
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
Sorry. No data so far.
-
From the Blog — Most Recent Articles
- Farewell to This Blog — and Hello to NEJM Voices March 2, 2026
- Some Ruminations on CROI — Still the Best HIV Meeting February 26, 2026
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing February 17, 2026
- Sometimes You Just Need to Get Input from a Real Human Being February 12, 2026
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
FROM NEJM — Recent Infectious Disease Articles- A Zoonotic Orthonairovirus from Febrile Patients in China September 3, 2026A new pathogenic orthonairovirus was identified in patients with a febrile illness in China. This virus was found in Haemaphysalis longicornis ticks in the same region.
- Pulmonary Nodules September 3, 2026This review summarizes the management of pulmonary nodules, with an emphasis on nodule type, imaging follow-up, cancer risk, and strategies to balance timely diagnosis with avoidance of unnecessary procedures.
- Fluid Resuscitation in Patients with Sepsis — For Whom the Balance Tolls September 3, 2026Improving the clinical treatment of patients with sepsis remains a major focus of critical care physicians worldwide.1,2 To date, few studies in either the pediatric or adult literature have established universal management principles that reliably improve outcomes, which attests to the heterogeneity of this syndrome. Fluid resuscitation is...
- Scrofuloderma September 3, 2026A 72-year-old man presented with a 2-month history of a painful lump on his neck. Cytologic analysis of fine-needle aspirate was consistent with suppurative lymphadenopathy. The lesion subsequently ulcerated and released purulent discharge.
- Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock September 3, 2026In children with septic shock, no significant difference was seen in the incidence of death, new renal-replacement therapy, or persistent kidney dysfunction with balanced fluid as compared with 0.9% saline for fluid resuscitation.
- A Zoonotic Orthonairovirus from Febrile Patients in China September 3, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
